Dr. Richard L. Gordon, DO

Media Releases

Get to know Hematologist-Oncologist Dr. Richard L. Gordon, who serves patients in Voorhees, New Jersey.

A professional in the fields of hematology and oncology, Dr. Gordon is a cancer specialist trained in blood disorders and the medical treatment of malignancies. He is a Partner at Comprehensive Cancer and Hematology Specialists, P.C. in Voorhees, New Jersey.  

Practicing medicine in New Jersey, he is affiliated with Virtua Marlton Hospital, Jefferson Stratford Hospital, Jefferson Cherry Hill Hospital, Jefferson Washington Township Hospital, and Virtua Voorhees Hospital.

Born in Philadelphia, Pennsylvania in 1943, Dr. Gordon received his Bachelor of Science degree at The American University in Washington, D.C. and attended medical school at Philadelphia College of Osteopathic Medicine. He graduated with his Doctor of Osteopathic Medicine degree in 1968, after which he went on to serve his internship and residency at NYC Health + Hospitals/Metropolitan. This was followed by a fellowship at Hahnemann University Hospital.

An expert in his field, the doctor is board-certified in internal medicine, hematology, and medical oncology by the American Osteopathic Board of Internal Medicine (AOBIM). The AOBIM is an organization that provides board certification to qualified Doctors of Osteopathic Medicine who specialize in the prevention, diagnosis, and treatment of disease in adults.

Hematology is the branch of medicine concerned with the study of the cause, prognosis, treatment, and prevention of diseases related to blood. Oncology is a branch of medicine that deals with the prevention, diagnosis, and treatment of cancer. A hematologist-oncologist is a physician who specializes in the diagnosis, treatment, or prevention of cancer, malignant blood diseases such as leukemia, lymphoma, and multiple myeloma, and blood disorders such as iron-deficiency anemia, clotting abnormalities, hemophilia, and sickle-cell disease.

With over five decades of clinical experience, Dr. Gordon is the recipient of Patients’ Choice Award (2018) and Compassionate Doctor Recognition (2018).

Recommended Articles

• The Promising Future of Gene Therapy and Lymphoma

  Non-Hodgkin lymphoma affects over 700,000 people in America alone. Though current treatments are moderately effective, especially for aggressive forms of the disease, more can be done to help people impacted by NHL. Researchers are doing just that by working to develop new, innovative treatment for...

• AstraZeneca Gains United States Approval for Lymphoma Drug

  Some forms of lymphoma are rarer than others. Most people can recognize Hodgkin lymphoma, but mantle cell lymphoma will strike them as a surprise.Because it is so rare, there are not as many drugs specific to this form of cancer. One has recently been approved in the United States, by the Food and...

• A Triathlon for Bloodwise

  Where would anyone be without friends? There have been many experiences where friends have been a bit of light in the dark. When 30-year-old Alexandra “Pixie” Flather from a town near Aylsham, England found out that her best friend was diagnosed with Leukemia, she decided to take action. At the...

• The Blow Self-Image Can Take During Lymphoma Treatment

  Many who have endured cancer treatment experience a blow to their self image, and cease to recognize the person looking back at them in the mirror.However, it does not have to be that way! Here are some of the most common changes, and how to cope with them.Skin changesYou may begin to see your skin...

• The Leukemia & Lymphoma Society to Expand Mission Against Blood Cancer

  On July 19, 2017, the Leukemia & Lymphoma Society, or LLS, proclaimed that they would be expanding their initiative to beat acute myeloid leukemia. Referred to as "Beat AML Master Trial", the project aims to test new and innovative treatments for those suffering from AML. For more information...

• The Lymphoma Research Foundation Announces Partnership with the Annals of Lymphoma

  The Lymphoma Research Foundation (LRF) is the nation’s largest non-profit organization for lymphoma research, and they just announced their partnership with the Annals of Lymphoma (AOL). This was all revealed in September during Blood Cancer Awareness Month. LRF is devoted to exclusively funding...